APPLICATIONS PUBLISHED 2 FEBRUARY 2005
Published: 1-Feb-2006
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Heterocycle inhibitors of potassium channel function
Bristol-Myers Squibb 1501467*
Warming and non-irritating anhydrous lubricant compsns
McNeil-PPC 1501478*
Capsules for dry powder inhalers and methods of making and using same
Nektar Therapeutics 1501479*
Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
Kapac 1501480*
Dispersions of lipids for use as therapeutic and cosmetic agents and intracellular delivery vehicles
BioTech Tools 1501481*
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
Esperion LUV Development 1501482*
Particulate materials
Nektar Therapeutics UK 1501483*
A process for the preparation of tablets from pharmaceutically active substances having favourable tabletting properties with a granulating liquid comprising microcrystalline cellulose
Egis Gyogyszergyar RT 1501484*
High drug load tablet
Novartis 1501485*
Extended release tablet containing felodipine
Sherman, Bernard Charles 1501486*
Capsule preparation
Warner-Lambert 1501487*
Use of GABA SB B /SB receptor positive modulators in gastro-intestinal disorders
Novartis 1501488*
Combination therapy for the treatment of cancer
Sloan-Kettering Institute for Cancer Research 1501489*
Methods for simultaneously treating mucositis and fungal infection
Collagenex Pharmaceuticals 1501490*
Methods and compsns for treatment of cancer pain
Novartis 1501491*
Anti-rhinovirus active agents
Unihart Corp 1501492*
Use of EPA and DHA in secondary prevention
Pronova Biocare 1501493*
Cell proliferating agents
Kimberley-Clark Worldwide 1501494*
Use of pleuromutilins for the treatment of disorders caused by heliobacter pylori
Sandoz 1501495*
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
Cydex 1501496*
Catechin multimers as therapeutic drug delivery agents
Larson, Drake 1501497*
Pharmaceutical composition comprising a lipase inhibitor and glucomannan
F Hoffmann-La Roche 1501498*
Trans-epicutaneous administration form for treating restless leg syndrome
Schwartz Pharma 1501499*
Carvedilol formulations
SmithKline Beecham Pharmco Puerto Rico 1501500*
Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrying out the method and a therapeutic composition using the material
Berta, Andras; Kolta, Peter; Kolta, Gergely; Lantos, Mihaly 1501501*
Carvedilol pharmasolve solvate
SmithKline Beecham Pharmco Puerto Rico 1501502*
Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatment of central nervous system disturbances
Polifarma 1501504*
1-substituted imidazole derivatives as NOS inhibitors
Schering 1501504*
Use of (3-(2-ethylphenyl)-5-methoxyphenyl)- 1h- 1,2,4 -triazole for the treatment of autoimmune diseases
Sigma-Tau Industrie Farmaceutiche Riunite 1501505*
FXR agonists for hepatoprotection and treatment of cholestasis
SmithKline Beecham; Curagen 1501506*
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
Merck & Co; Merck, Sharp & Dohme 1501507*
Inhibitors of histone deacetylase
AstraZeneca 1501508*
Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
Merck 1501509*
The treatment of pain with ifenprodil
Arakis 1501510*
Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
Washington University 1501511*
4-azasteroid derivatives as androgen receptor modulators
Merck 1501512*
Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
Ardent Pharmaceuticals 1501513*
Protein kinase modulators and methods of use
Exelixis 1501514*
Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
Pfizer 1501515*
A process for the preparation of benazepril hydrochloride
Dipharma 1501516*
Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
Boehringer Ingelheim Pharma 1501517*
Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
Novartis 1501518*
9-oxime macrolide antibacterials
Abbott Laboratories 1501519*
Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels anticancer agents
Diakron Pharmaceuticals 1501520*
Long acting compositions comprising zidovudine and lamivudine
Lupin 1501521*
Preblocking with non-HA gags increases effectiveness of ha conjugated anticancer agents
University of Utah Research Foundation 1501522*
Carbon monoxide as a biomarker and therapeutic agent
Yale University; The Johns Hopkins University, School of Medicine 1501523*
Internal image antibodies for optical imaging and therapy
Mallinckrodt 1501524*
Method for producing preparations rich in tocotrienol
Vis-Vitalis Lizenz- und Handels 1501525*
Curcumin for the prevention and/or treatment of tissue damage
Isis Innovation 1501526*
Use of mastic and its components for the control of microbial infections
Lavipharm 1501527*
Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family
Wandij, Thomas 1501528*
Prostaglandin F2 alpha analogs in combination with antimicrobial for treating glaucoma
Cayman Chemical Company 1501530*
Method for treating anxiety and mood disorders in older subjects
Eli Lilly 1501531*
Peptide inhibitors of protein kinase C
The Board of Trustees of the Leland Stanford Junior University 1501532*
Peptide inhibitors of protein kinase c ϝ for pain management
The Board of Trustees of the Leland Stanford Junior University 1501533*
Desmopressin in orodispersible dosage form
Ferring 1501534*
Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents thereof
Recepticon 1501535*
Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
Applera 1501536*
Mannose binding lectin and uses thereof
The Council of the Queensland Institute of Medical Research 1501538*
Use of alpha-S2 casein precursor-derived peptides
Pepsyn 1501539*
Method for control of depression using C terminal growth hormone (GH) fragment
Metabolic Pharmaceuticals 1501539*
T-cell epitodes in carboxypeptidase G2
Merck Patent 1501540*
Encapsulated cells to elicit immune responses
Canadian Blood Supply Services 1501541*
Improved polysaccharide and glycoconjugate vaccines
Biosynth 1501542*
Use of modified novirhabdoviruses to obtain vaccines
Institut National de la Recherche Agronomique (INRA) 1501543*
Alcam and alcam modulators
Raven Biotechnologies 1501544*
Use of TNF-alpha antibodies and another drug
Abbott Laboratories 1501545*
Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
Hexal 1501546*
Methods and compositions for treating, preventing or delaying onset of a neoplasm
Pharmacia & Upjohn 1501547*
Chemically activated carboxypolysaccharides and uses
Fziomed 1501548*
Lyophilised and liquid preparations comprising a polysaccharide derivative of camptothecin
Tanabe Seiyaku 1501549*
